Print Page  |  Close Window


ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®

More »
Stock Quote
Change (%)0.00 (0.00%)
Refresh quote
Real-Time Level 2 Quote
Recent NewsMore »
03/11/19ChromaDex to Present at the 31st Annual ROTH Conference
LOS ANGELES, March 11, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, Chairman and Co-Founder, Frank Jaksch, and Chief Financial Officer, Kevin Farr, will present at the 31st annual ROTH Capital Partners Conference at the Ritz-Carlton in Dana Point, CA. The ChromaDex management team is scheduled to present on Monday, March 18, at 3:30 p.m. Pacific Time.  ChromaDex management will also attend one-on-one meetings with instit... 
Printer Friendly Version
03/08/19ChromaDex Brings TRU NIAGEN® to SXSW® 2019
TRU NIAGEN® milestones to be highlighted at South by Southwest® SXSW® gathering of global professionals LOS ANGELES, March 08, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today it will feature its cellular health product, TRU NIAGEN®, at SXSW®, as it marks the achievement of attaining over 160 research collaborations around the world on its patented NIAGEN® (nicotinamide riboside) ingredient. "To help SXSW® attendees who need an extra boost in their busy lives, we'll b... 
Printer Friendly Version
03/07/19ChromaDex Corporation Reports 2018 Financial Results
- Full Year 2018 Net Revenues Increased by 49% to $31.6 Million and Fourth Quarter 2018 Net Revenues Increased by 20% to $9.1 Million - Fourth Quarter 2018 Highlights vs. Fourth Quarter 2017 Entered into a global license and supply agreement with Nestlé Health Science (“NHSc”), which provides NHSc with the exclusive right to include TRU NIAGEN® in its branded medical nutrition products and co-exclusive rights to include TRU NIAGEN in its protein based ready to drink or loose powder bever... 
Printer Friendly Version
What's New
March 2019 Investor Presentation PDF
Q4 2018 Earnings Presentation  PDF
2018 Annual Report on Form 10K  PDF
December 2018 Investor Presentation PDF
ChromaDex Investor FAQs Third Quarter 2018 PDF
Q3 2018 Earnings Presentation PDF
September 2018 Investor Presentation PDF
July 2018 Investor Presentation PDF
2018 Proxy Statement  PDF
Get help downloading or viewing the above file types
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Chromadex Corp posts new information to the site. Just enter your e-mail address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed.